Table V.
Event-free and Overall Survival for Tumor Category by Clinical Stage
| Histological Category | Overall Number of Patients | Number with Survival data | 5-year EFS ± SE (%) | EFS p-value | 5-year OS ± SE (%) | OS p-value |
|---|---|---|---|---|---|---|
| GN-maturing | ||||||
| Stage 1, 2, 3 | 36 | 34 | 100 | 100 | ||
| Stage 4 | 0 | 0 | --- | NA | --- | NA |
|
| ||||||
| GNB-intermixed | ||||||
| Stage 1, 2, 3 | 187 | 179 | 94.1 ± 4.3 | 97.0 ± 3.2 | ||
| Stage 4 | 2 | 2 | --- | NA | --- | NA |
|
| ||||||
| GNB-nodular FS | ||||||
| Stage 1, 2, 3 | 56 | 55 | 92.6 ± 6.3 | 100 | ||
| Stage 4 | 3 | 3 | 100 | NA | 100 | NA |
|
| ||||||
| GNB-nodular US | ||||||
| Stage 1, 2, 3 | 116 | 114 | 80.1 ± 8.0 | 86.2 ± 7.0 | ||
| Stage 4 | 132 | 132 | 16.7 ± 5.8 | <.0001 | 35.9 ± 7.0 | <.0001 |
EFS = Event-free survival; OS = Overall survival; SE = standard error; NA = not applicable due to no event; --- = No patients at risk at 5 years; GN-maturing = Ganglioneuroma, maturing subtype; GNB-intermixed = Ganglioneuroblastoma, intermixed; GNB-nodular FS = Ganglioneuroblastoma, nodular Favorable Subset; GNB-nodular US = Ganglioneuroblastoma, nodular Unfavorable Subset